WO2001064220A1 - UTILISATION DE TRIMETAZIDINE POUR INHIBER L'ACYL-CoA ACETYLTRANSFERASE - Google Patents

UTILISATION DE TRIMETAZIDINE POUR INHIBER L'ACYL-CoA ACETYLTRANSFERASE Download PDF

Info

Publication number
WO2001064220A1
WO2001064220A1 PCT/FR2001/000535 FR0100535W WO0164220A1 WO 2001064220 A1 WO2001064220 A1 WO 2001064220A1 FR 0100535 W FR0100535 W FR 0100535W WO 0164220 A1 WO0164220 A1 WO 0164220A1
Authority
WO
WIPO (PCT)
Prior art keywords
document
page
vol
relevant
documents
Prior art date
Application number
PCT/FR2001/000535
Other languages
English (en)
Inventor
Gary Lopaschuk
Arnaud Lucien
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Priority to AU2001237484A priority Critical patent/AU2001237484A1/en
Publication of WO2001064220A1 publication Critical patent/WO2001064220A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne l'utilisation de la trimétazidine ou d'un de ses sels d'addition à un acide pharmaceutiquement acceptable pour l'obtention de compositions pharmaceutiques destinées à inhiber l'acyl-CoA acétyltransférase, qui seront utilisées dans diverses pathologies cardiaques et coronariennes, dans le traitement d'angiapathies, de la claudication, intermittente, des troubles de l'orientation et de l'équilibre, de la dégénérescence moléculaire liée à l'âge, de la rétinopathie diabétique ou de toute autre phatologie liée à des troubles de métabolisme cellulaire énergétique.

Claims

- 5 -
Résultats :
L'ajout de 1 μM de trimétazidine produit une diminution de l'oxydation du palmitate ainsi qu'une augmentation de l'oxydation du glucose. La vitesse de la glycolyse reste inchangée. Ces effets ne sont significatifs qu'en présence de palmitate. Au cours de l'ischémie, l'oxydation du glucose est fortement stimulée (+ 210 %).
Conclusion :
La trimétazidine réduit la β-oxydation des acides gras à chaînes longues. Ceci est associé à une stimulation de l'oxydation du glucose, en aérobie comme lors d'une période d'ischémie. La glycolyse restant inchangée, un meilleur couplage avec l'oxydation du glucose est attendu.
A. CLASSIFICATION OF SUBJECT ATTER
IPC 7 A61K31/495 A61P39/00 A61P39/06 A61P9/10 A61P9/04 A61P9/08 A61P27/16 A61P27/02
According to International Patent Classification (IPC) orto both national classification and IPC
B. FIELDS SEARCHED
Minimum documentation searched (classification System followed by classification symbols)
IPC 7 A61K
Documentation searched other than minimum documentation to the extent that such documents are included in the tields searched
Electronic data base consulted dunng the international search (name of data base and, where practical search terms used)
EPO-I nternal , CHE ABS Data
C. DOCUMENTS CONSIDERED TO BE RELEVANT
Category ° Citation of document with indication where appropπate, of the relevant passages Relevant to daim No
P , X LUCIEN A ET AL : "THE ANTI-ANGINAL ACTIONS 1 , 2
OF TRIMETAZIDINE ARE A RESULT OF A
DECREASE IN CARDIAC FATTY ACID OXIDATION
RATES DUE TO INHI BITION 0FL0NG CHAIN
3-KET0 ACYL COA THIOLASE "
JOURNAL OF MOLECULAR AND CELLULAR
CARDI0L0GY , XX , XX , vol . 32 , no . 5 , 10 May 2000 ( 2000-05-10 ) , page A42 XP000978197
ISSN : 0022-2828 abstract
Further documents are listed m the continuation of box C Patent family members are listed m annex
° Spécial catégories of cited documents
"T" later document published after the international filing date or pπonty date and not in conflict with the application but
"A" document definmg the gênerai state of the art which is not cited to understand the pnnciple or theory underlying the considered to be of particular relevance invention "E" earlier document but published on or after the international "X" document of particular relevance the claimed invention filing date cannot be considered novel or cannot be considered to "L" document which may throw doubts on pπonty claιm(s) or involve an inventive step when the document is taken alone which is cited to establish the publication date of another "Y" document of particular relevance, the claimed invention citation or other spécial reason (as specrfied) cannot be considered to involve an inventive step when the
"O" document referring to an oral disclosure, use exhibition or document is combmed with one or more other such docuother means ments such combination being obvious to a person skilled
"P" document published prior to the international filing date but m the art laterthan the pnoπty date claimed "S" document member of the sa e patent family
Date of the actual completion of the international search Date of mailing of the international search report
7 August 2001 14/08/2001
Name and mailing address ot the ISA Autho zed officer
European Patent Office P B 5818 Patentlaan 2 NL - 2280 HV Ri|swi|k Tel (+31-70) 340-2040, Tx 31 651 epo ni Fax (+31-70) 340-3016 Gac , G
Form PCT. ISA.210 (second s eet) (July 1992) α(Contiruιation) DOCUMENTS CONSIDERED TO BE RELEVANT
Category ° Citation of document, with indication.where appropriate, of the relevant passages Relevant to daim No
DATABASE MEDLINE 'Online!
AN : 97344544,
XP002158323 abstract
& POGATSA: "New concepts in the therapy of diabetic cardiopathies"
ORVOSI HETILAP, vol. 138, no. 3, 8 June 1997 (1997-06-08), pages 1491-1494, abstract
FR 2 490 963 A (SCIENCE UNION & CIE) 2-5 2 April 1982 (1982-04-02) the whole document
US 3 262 852 A (J. SERVIER) 2-5 cited in the application the whole document
FR 805 M (BI0FARMA) 2-5 cited in the application page 2
LOPASCHUK G D ET AL: "TRIMETAZIDINE 1,2
INHIBITS FATTY ACID OXIDATION IN THE
HEART"
TELETRAFFIC ANALYSIS AND COMPUTER
PERFORMANCE EVALUATION, PROCEEDINGS OF THE
INTERNATIONAL SEMINAR, ELSEVIER SCIENCE
PUBLISHERS B.V.NL, vol. 30, no. 6, June 1998 (1998-06), page
A112 XP000978199 the whole document
SPEDDING M ET AL: "MEDICAMENTS 1,2
INTERAGISSANT AVEC LES MITOCHONDRIES:
EFFETS ANTI-ISCHEMIQUES DE LA
TRIMETAZIDINE"
THERAPIE, DOIN, PARIS, FR, vol. 54, no. 5, September 1999 (1999-09), pages 627-635, XP000978190
ISSN: 0040-5957 page 631, right-hand column -page 633
LOPASCHUK: "Optimizaing cardiac energy 1,2 metabolism: a new approach to treating ischémie heart disease"
EUR0PEAN HEART JOURNAL, SUPPL., vol. 1, no. 0, - 1999 pages 032-039,
XP000978353
* le document en entier, surtout page 037 colonne de gauche et page 035 Tableau 1 *
-/--
Form PCT'ISA/210 (continuation of second sheet) (July 1992) a e 2 of 4 PCT/FR 01/00535
C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT
Category ° Citation of document, with indication.where appropriate, of the relevant passages Relevant to daim No
DI GIR0LAM0 ET AL.: "Trimétazidine 1,2 inhibits fatty acid beta -oxidation, resulting in less production and accumulation of lactate and H+ during ischemia"
CARDIOVASC. DRUGS THER. , vol. 13, no. 1, 1999, page 18 XP000978472 abstract
KANTOR ET AL.: "Fatty acid oxidation in 1,2 the reperfused ischémie heart"
AM. J. MED. SCI., vol. 318, no. 1, 1999, pages 3-14,
XP000978354
* le document en entier, surtout page 9 colonne de droite paragraphe 3, page 10 colonne de droite et Tableau 2; pages 11 et 12 *
STANLEY ET AL.: "Régulation of myocardial 1,2 carbohydrate metabolism under normal and ischémie conditions. Potential for pharmacol ogi cal i nterventi ons " CARDIOVASCULAR RESEARCH, vol. 33, no. 2, February 1997 (1997-02), pages 243-257, XP000978213 the whole document
JACKSON: "Clinical benefits of a 1,2 metabolic approach to the menegement of coronary patients"
EUR0PEAN HEART JOURNAL, vol. 1, no. suppl . , 1999, pages 028-031,
XP000978351 page 029 page 030, left-hand column, paragraph 1
W0 97 00678 A (THE QUEEN ELIZABETH 1-5 H0SPITAL) 9 January 1997 (1997-01-09) page 7 page 15, une 9 - une 12
EP 0 533 579 A (ADIR ET A0.) 1-5 24 March 1993 (1993-03-24) page page
-/-
Form PCT/ISA/210 (continuation of second sheet) (July 1992) C.(Contιnuation) DOCUMENTS CONSIDERED TO BE RELEVANT
Category ° Citation of document, with indication.where appropriate, ot the relevant passages Relevant to daim No
CARGNONI A ET AL: "INSIGHT INTO 2-5
CYTOPROTECTION WITH METABOLIC AGENTS"
EUROPEAN HEART JOURNAL, THE EUROPEAN
SOCIETY OF CARDIOLOGY, XX, vol. 1, no. SUPPL 0,
August 1999 (1999-08), pages 040-048,
XP000978352
ISSN: 0195-668X the whole document
DEMAISON L ET AL: "INFLUENCE 0F THE
ANTI-ISCHEMIC TRIMETAZIDINE ON CARDIAC
ENERGY METABOLISM"
JOURNAL 0F MOLECULAR AND CELLULAR
CARDIOLOGY, XX, XX, vol. 25, no. SUPPL 4, 1993, page S15
XP000978201
ISSN: 0022-2828 abstract
Form PCT/ISA/210 (continuation ot seconα sheet) (July 1992) a e 4 of 4 Information on patent family members
PCT/FR 01/00535
Patent document Publication Patent family Publication cited in search report date member(s) date
FR 2490963 A 02-04-1982 AU 550761 B 10-04-1986
AU 7574481 A 08-04-1982
BE 890568 A 30-03-1982
CA 1169775 A 26-06-1984
CH 650675 A 15-08-1985
DE 3139005 A 06-05-1982
GB 2084019 A, B 07-04-1982
GR 75803 A 02-08-1984
IE 51764 B 18-03-1987
IT 1171557 B 10-06-1987
LU 83654 A 14-04-1982
NZ 198435 A 03-02-1984
US 4407801 A 04-10-1983
ZA 8106766 A 29-09-1982
US 3262852 A NONE
FR 805 M N0NE
WO 9700678 A 09-01-1997 AU 6115296 A 22-01-1997
EP 533579 A 24-03-1993 FR 2681324 A 19-03-1993
AT 145899 T 15-12-1996
AU 647964 B 31-03-1994
AU 2453792 A 25-03-1993
CA 2078520 A 19-03-1993
DE 69215626 D 16-01-1997
DE 69215626 T 12-06-1997
DK 533579 T 26-05-1997
ES 2097299 T 01-04-1997
GR 3022322 T 30-04-1997
JP 1942690 C 23-06-1995
JP 5194451 A 03-08-1993
JP 6076396 B 28-09-1994
NZ 244370 A 27-09-1994
US 5283246 A 01-02-1994
ZA 9207165 A 24-03-1993
l-orm PCT ISA/210 (patent family annex) (July 1992) A. CLASSEMENT DE L'OBJET DE LA DEMANDE
C IB 7 A61K31/495 A61P39/00 A61P39/06 A61P9/10 A61P9/04
A61P9/08 A61P27/16 A61P27/02
Selon la classification internationale des brevets (CIB) ou a la fois selon la classification nationale et la CIB
B. DOMAINES SUR LESQUELS LA RECHERCHE A PORTE
Documentation minimale consultée (système de classification SUIVI des symboles de classement)
C IB 7 A61K
Documentation consultée autre que la documentation minimale dans la mesure ou ces documents relèvent des domaines sur lesquels a porte la recherche
Base de données électronique consultée au cours de la recherche internationale (nom de la base de données et si réalisable, termes de recherche utilises)
EPO-Internal , CHEM ABS Data
C. DOCUMENTS CONSIDERES COMME PERTINENTS
Catégorie ° Identification des documents cites avec, le cas échéant l'indication des passages pertinents no des revendications visées
p , χ LUCIEN A ET AL : "THE ANTI-ANGINAL ACTIONS 1 , 2
OF TRIMETAZIDINE ARE A RESULT OF A
DECREASE IN CARDIAC FATTY ACID OXIDATION
RATES DUE TO INHI BITION OFLONG CHAIN
3-KETO ACYL COA THIOLASE "
JOURNAL OF MOLECULAR AND CELLULAR
CARDIOLOGY , XX , XX , vol . 32 , no . 5 , 10 mai 2000 (2000-05-10 ) , page A42 XP000978197
ISSN : 0022-2828 abrégé
-/--
Voir la suite du cadre C pour la fin de la liste des documents Les documents de familles de brevets sont indiques en annexe
° Catégories spéciales de documents cites
"T" document ultérieur publie après la date de dépôt international ou la date de priorité et n'appartenenant pas a l'état de la
"A" document définissant l'état gênerai de la technique non technique pertinent mais cite pour comprendre le principe considère comme particulièrement pertinent ou la theoπe constituant la base de l'invention
"E" document anteπeur mais publie a la date de dépôt international ou après cette date •X" document particulièrement pertinent, l'inven tion revendiquée ne peut être considérée comme nouvelle ou comme impliquant une activité
"L" document pouvant jeter un doute sur une revendication de inventive par rapport au document considère isolement priorité ou cite pour déterminer la date de publication d'une "Y" document particulièrement pertinent, l'inven tion revendiquée autre citation ou pour une raison spéciale (telle qu'indiquée) ne peut être considérée comme impliquant une activité inventive
"O" document se référant a une divulgation orale a un usage, a lorsque le document est associe a un ou plusieurs autres une exposition ou tous autres moyens documents de même nature, cette combinaison étant évidente
"P" document publie avant la date de dépôt international, mais pour une personne du métier postérieurement a la date de priorité revendiquée '&' document qui fait partie de la même famille de brevets
Date a laquelle la recherche internationale a ete effectivement achevée Date d'expédition du présent rapport de recherche internationale
7 août 2001 14/08/2001
Nom et adresse postale de l'administration chargée de la recherche internationale Fonctionnaire autorise Office Européen des Brevets. P B 5818 Patentlaan 2 NL - 2280 HV Ri|swi|k Tel (+31-70) 340-2040, Tx 31 651 epo ni, Fax (+31-70) 340-3016 Gac , G
Formulaire PCT'!SA/210 (deuxième feuille) {juillet 1992) a e de 4 C.(suite) DOCUMENTS CONSIDERES COMME PERTINENTS
Catégorie ° Identification des documents cités, avec, le cas échéant, I lndicationdes passages pertinents no. des revendications visées
DATABASE MEDLINE 'en ligne!
AN : 97344544,
XP002158323 abrégé
& POGATSA: "New concepts in the therapy of di abêtie cardiopathies"
0RV0SI HETILAP, vol. 138, no. 3, 8 juin 1997 (1997-06-08), pages 1491-1494, abrégé
FR 2 490 963 A (SCIENCE UNION & CIE) 2-5 2 avril 1982 (1982-04-02) le document en entier
US 3 262 852 A (J. SERVIER) 2-5 cité dans la demande le document en entier
FR 805 M (BI0FARMA) 2-5 cité dans la demande page 2
LOPASCHUK G D ET AL: "TRIMETAZIDINE 1,2
INHIBITS FATTY ACID OXIDATION IN THE
HEART"
TELETRAFFIC ANALYSIS AND COMPUTER
PERFORMANCE EVALUATION, PROCEEDINGS 0F THE
INTERNATIONAL SEMINAR, ELSEVIER SCIENCE
PUBLISHERS B.V.NL, vol. 30, no. 6, juin 1998 (1998-06), page
A112 XP000978199 le document en entier
SPEDDING M ET AL: "MEDICAMENTS 1,2
INTERAGISSANT AVEC LES MIT0CH0NDRIES:
EFFETS ANTI-ISCHEMIQUES DE LA
TRIMETAZIDINE"
THERAPIE, DOIN, PARIS, FR, vol. 54, no. 5, septembre 1999 (1999-09), pages 627-635, XP000978190
ISSN: 0040-5957 page 631, colonne de droite -page 633
LOPASCHUK: "Optimizaing cardiac energy 1,2 metabolism: a new approach to treating ischémie heart disease"
EUROPEAN HEART JOURNAL, SUPPL., vol. 1, no. 0, - 1999 pages 032-039,
XP000978353
* le document en entier, surtout page 037 colonne de gauche et page 035 Tableau 1 *
Formulaire PCT/1SA 210 (suite de la deuxième feuille) (juillet 1992) a e 2 de 4 C.(suite) DOCUMENTS CONSIDERES COMME PERTINENTS
Catégorie ° Identification des documents cités, avec, le cas échéant, l'indicationdes passages pertinents no. des revendications visées
DI GIR0LAM0 ET AL.: "Trimétazidine 1,2 inhibits fatty acid beta -oxidation, resulting in less production and accumulation of lactate and H+ during ischemia"
CARDIOVASC. DRUGS THER., vol. 13, no. 1, 1999, page 18 XP000978472 abrégé
KANTOR ET AL.: "Fatty acid oxidation in 1,2 the reperfused ischémie heart"
AM. J. MED. SCI., vol. 318, no. 1, 1999, pages 3-14,
XP000978354
* le document en entier, surtout page 9 colonne de droite paragraphe 3, page 10 colonne de droite et Tableau 2; pages 11 et 12 *
STANLEY ET AL.: "Ré ulation of myocardial 1,2 carbohydrate metabolism under normal and ischémie conditions. Potential for phar acological interventions" CARDIOVASCULAR RESEARCH, vol. 33, no. 2, février 1997 (1997-02), pages 243-257, XP000978213 le document en entier
JACKSON: "Clinical benefits of a 1,2 etabolic approach to the enegement of coronary patients"
EUROPEAN HEART JOURNAL, vol. 1, no. suppl . , 1999, pages 028-031,
XP000978351 page 029 page 030, colonne de gauche, alinéa 1
W097 00678 A (THE QUEEN ELIZABETH 1-5
H0SPITAL) 9 janvier 1997 (1997-01-09) page 7 page 15, ligne 9 - ligne 12
EP 0 533 579 A (ADIR ET A0.) 1-5 24 mars 1993 (1993-03-24) page 2 page 4
CARGN0NI A ET AL: "INSIGHT INT0 2-5
CYT0PR0TECTI0N WITH METABOLIC AGENTS"
EUROPEAN HEART JOURNAL, THE EUROPEAN
SOCIETY 0F CARDIOLOGY, XX, vol. 1, no. SUPPL 0, août 1999 (1999-08), pages 040-048, XP000978352
ISSN: 0195-668X le document en entier
-/-
Formulaire PCT'ISA/210 (suite de la deuxième feuille) (juillet 1992) d 4 PCT/FR 01/00535
C. (suite) DOCUMENTS CONSIDERES COMME PERTINENTS
Catégorie ° Identification des documents cites, avec. le cas échéant, l'indicationdes passages pertinents no des revendications visées
DEMAISON L ET AL: "INFLUENCE OF THE
ANTI-ISCHEMIC TRIMETAZIDINE ON CARDIAC
ENERGY METABOLISM"
JOURNAL OF MOLECULAR AND CELLULAR
CARDIOLOGY, XX, XX, vol . 25, no. SUPPL 4, 1993, page S15
XP000978201
ISSN: 0022-2828 abrégé
Formulaire PCT/ISA'210 (suite de la deuxième feuille) (juillet 1992) Renseignements relatifs aux membres de familles de brevets
PCT/FR 01/00535
Document brevet cite Date de embre(s) de la Date de au rapport de recherche publication famille de brevet(s) publication
FR 2490963 A 02-04-1982 AU 550761 B 10-04-1986
AU 7574481 A 08-04-1982
BE 890568 A 30-03-1982
CA 1169775 A 26-06-1984
CH 650675 A 15-08-1985
DE 3139005 A 06-05-1982
GB 2084019 A, B 07-04-1982
GR 75803 A 02-08-1984
IE 51764 B 18-03-1987
IT 1171557 B 10-06-1987
LU 83654 A 14-04-1982
NZ 198435 A 03-02-1984
US 4407801 A 04-10-1983
ZA 8106766 A 29-09-1982
US 3262852 A AUCU 1
FR 805 M AUCU 1
WO 9700678 A 09-01-1997 AU 6115296 A 22-01-1997
EP 533579 A 24-03-1993 FR 2681324 A 19-03-1993
AT 145899 T 15-12-1996
AU 647964 B 31-03-1994
AU 2453792 A 25-03-1993
CA 2078520 A 19-03-1993
DE 69215626 D 16-01-1997
DE 69215626 T 12-06-1997
DK 533579 T 26-05-1997
ES 2097299 T 01-04-1997
GR 3022322 T 30-04-1997
JP 1942690 C 23-06-1995
JP 5194451 A 03-08-1993
JP 6076396 B 28-09-1994
NZ 244370 A 27-09-1994
US 5283246 A 01-02-1994
ZA 9207165 A 24-03-1993
Formulaire PCT'ISA/210 (annexe familles de brevets) (juillet 1992)
PCT/FR2001/000535 2000-02-25 2001-02-23 UTILISATION DE TRIMETAZIDINE POUR INHIBER L'ACYL-CoA ACETYLTRANSFERASE WO2001064220A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001237484A AU2001237484A1 (en) 2000-02-25 2001-02-23 Use of trimetazidine to inhibit acyl-coa acetyl transferase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR00/02385 2000-02-25
FR0002385A FR2805463B1 (fr) 2000-02-25 2000-02-25 UTILISATION DE LA TRIMETAZIDINE POUR L'OBTENTION DE COMPOSITIONS PHARMACEUTIQUES DESTINEES A INHIBER L'ACYL-CoA ACETYLTRANSFERASE

Publications (1)

Publication Number Publication Date
WO2001064220A1 true WO2001064220A1 (fr) 2001-09-07

Family

ID=8847399

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/000535 WO2001064220A1 (fr) 2000-02-25 2001-02-23 UTILISATION DE TRIMETAZIDINE POUR INHIBER L'ACYL-CoA ACETYLTRANSFERASE

Country Status (3)

Country Link
AU (1) AU2001237484A1 (fr)
FR (1) FR2805463B1 (fr)
WO (1) WO2001064220A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645994B1 (en) 2001-06-01 2003-11-11 Alcon, Inc. Method of treating dry eye disorders

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR805M (fr) * 1960-06-30 1961-09-01
US3262852A (en) * 1966-07-26 Vasodilator and anti-anginose com- pounds containing methoxy benzyl piperazines and method of using the same
FR2490963A1 (fr) * 1980-09-30 1982-04-02 Science Union & Cie Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine
EP0533579A1 (fr) * 1991-09-18 1993-03-24 Adir Et Compagnie Nouveaux dérivés de la trimétazidine, leur procédé de préparation et les compositions pharmaceutiques les contenant
WO1997000678A1 (fr) * 1995-06-23 1997-01-09 The Queen Elizabeth Hospital Procedes concernant le traitement et l'isolement de composes pour traiter des etats pathologiques ischemiques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3262852A (en) * 1966-07-26 Vasodilator and anti-anginose com- pounds containing methoxy benzyl piperazines and method of using the same
FR805M (fr) * 1960-06-30 1961-09-01
FR2490963A1 (fr) * 1980-09-30 1982-04-02 Science Union & Cie Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine
EP0533579A1 (fr) * 1991-09-18 1993-03-24 Adir Et Compagnie Nouveaux dérivés de la trimétazidine, leur procédé de préparation et les compositions pharmaceutiques les contenant
WO1997000678A1 (fr) * 1995-06-23 1997-01-09 The Queen Elizabeth Hospital Procedes concernant le traitement et l'isolement de composes pour traiter des etats pathologiques ischemiques

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CARGNONI A ET AL: "INSIGHT INTO CYTOPROTECTION WITH METABOLIC AGENTS", EUROPEAN HEART JOURNAL, THE EUROPEAN SOCIETY OF CARDIOLOGY, XX, vol. 1, no. SUPPL O, August 1999 (1999-08-01), pages O40 - O48, XP000978352, ISSN: 0195-668X *
DATABASE MEDLINE XP002158323 *
DEMAISON L ET AL: "INFLUENCE OF THE ANTI-ISCHEMIC TRIMETAZIDINE ON CARDIAC ENERGY METABOLISM", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, XX, XX, vol. 25, no. SUPPL 4, 1993, pages S15, XP000978201, ISSN: 0022-2828 *
DI GIROLAMO ET AL.: "Trimetazidine inhibits fatty acid beta -oxidation, resulting in less production and accumulation of lactate and H+ during ischemia", CARDIOVASC. DRUGS THER., vol. 13, no. 1, 1999, pages 18, XP000978472 *
JACKSON: "Clinical benefits of a metabolic approach to the menegement of coronary patients", EUROPEAN HEART JOURNAL, vol. 1, no. suppl., 1999, pages O28 - O31, XP000978351 *
KANTOR ET AL.: "Fatty acid oxidation in the reperfused ischemic heart", AM. J. MED. SCI., vol. 318, no. 1, 1999, pages 3 - 14, XP000978354 *
LOPASCHUK G D ET AL: "TRIMETAZIDINE INHIBITS FATTY ACID OXIDATION IN THE HEART", TELETRAFFIC ANALYSIS AND COMPUTER PERFORMANCE EVALUATION, PROCEEDINGS OF THE INTERNATIONAL SEMINAR,ELSEVIER SCIENCE PUBLISHERS B.V,NL, vol. 30, no. 6, June 1998 (1998-06-01), pages A112, XP000978199 *
LOPASCHUK: "Optimizaing cardiac energy metabolism: a new approach to treating ischemic heart disease", EUROPEAN HEART JOURNAL, SUPPL., vol. 1, no. 0, - 1999, pages 032 - 039, XP000978353 *
LUCIEN A ET AL: "THE ANTI-ANGINAL ACTIONS OF TRIMETAZIDINE ARE A RESULT OF A DECREASE IN CARDIAC FATTY ACID OXIDATION RATES DUE TO INHIBITION OFLONG CHAIN 3-KETO ACYL COA THIOLASE", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY,XX,XX, vol. 32, no. 5, 10 May 2000 (2000-05-10), pages A42, XP000978197, ISSN: 0022-2828 *
POGATSA: "New concepts in the therapy of diabetic cardiopathies", ORVOSI HETILAP, vol. 138, no. 3, 8 June 1997 (1997-06-08), pages 1491 - 1494 *
SPEDDING M ET AL: "MEDICAMENTS INTERAGISSANT AVEC LES MITOCHONDRIES: EFFETS ANTI-ISCHEMIQUES DE LA TRIMETAZIDINE", THERAPIE,DOIN, PARIS,FR, vol. 54, no. 5, September 1999 (1999-09-01), pages 627 - 635, XP000978190, ISSN: 0040-5957 *
STANLEY ET AL.: "Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions. Potential for pharmacological interventions", CARDIOVASCULAR RESEARCH, vol. 33, no. 2, February 1997 (1997-02-01), pages 243 - 257, XP000978213 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645994B1 (en) 2001-06-01 2003-11-11 Alcon, Inc. Method of treating dry eye disorders

Also Published As

Publication number Publication date
FR2805463A1 (fr) 2001-08-31
AU2001237484A1 (en) 2001-09-12
FR2805463B1 (fr) 2003-01-24

Similar Documents

Publication Publication Date Title
Giacobini Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer disease
Vinegar et al. Some quantitative temporal characteristics of carrageenin-induced pleurisy in the rat
ÅBerg et al. Preliminary clinical test of zimelidine (H 102/09), a new 5‐HT uptake inhibitor
Lin et al. A new flavone C-glycoside and antiplatelet and vasorelaxing flavones from Gentiana arisanensis
Sozio et al. Designing prodrugs for the treatment of Parkinson's disease
Becker et al. Safety assessment of trimoniums as used in cosmetics
US20130123357A1 (en) Methods for Providing Enhanced Resveratrol Activity Using 4-Acetoxy-Resveratrol
Ma et al. Protective effects of lovastatin on vascular endothelium injured by low density lipoprotein
WO2001001980A1 (fr) Procedes d'amelioration de troubles neuropsychiatriques par inhibition du transport inactivant de substances cannabinoides endogenes
WO2001064220A1 (fr) UTILISATION DE TRIMETAZIDINE POUR INHIBER L'ACYL-CoA ACETYLTRANSFERASE
PT2420496E (pt) Composto antiepiléptico, hipocolesterolémico e neuroprotector
Gamzu et al. Recent development in 2‐pyrrolidinone‐containing nootropics
Dhall et al. Studies on urea co-inclusion complexes of simvastatin for improvement of pharmaceutical characteristics
Pati et al. 1, 3‐Diaryl‐2‐propenones and 2‐benzylidene‐1, 3‐indandiones: A quest for compounds displaying greater toxicity to neoplasms than normal cells
JP2001172180A (ja) アポｂ分泌／ｍｔｐ阻害剤の使用
EP1793813A2 (fr) Traitement du trouble d'hyperactivite avec deficit de l'attention (thada)
TW202042794A (zh) 治療神經退化疾病之方法
Li et al. Preparation, transportation mechanisms and brain-targeting evaluation in vivo of a chemical delivery system exploiting the blood–cerebrospinal fluid barrier
Izzo Jr et al. Reduction in human urinary MHPG excretion by guanethidine: Urinary MHPG as index of sympathetic nervous activity
JP3236157B2 (ja) 育毛剤及びこれを含有する頭髪用の化粧料
EP0477552A1 (fr) Utilisation de lactones cycliques à dix chaînons comme régulateurs des lipides
US12078642B2 (en) Methods for evaluating and improving cognitive function
JP2001139491A (ja) ａｐｏＢ分泌／ＭＴＰ阻害剤及び抗肥満剤の使用
Fiume et al. Safety assessment of alkyl ethylhexanoates as used in cosmetics
de la Rosa‐Lugo et al. Affinin and hexahydroaffinin: Chemistry and toxicological profile

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP